T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.08% |
| 2 | Healthcare | 16.24% |
| 3 | Consumer Discretionary | 15.33% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
951
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $58.9M | 0.01% |
424,217
+53,488
| +14% | +$6.68M |
|
952
Howard Hughes
HHH
$4.04B
| $58.9M | 0.01% |
703,386
+232,847
| +49% | +$20.1M |
|
953
Portland General Electric
POR
$5.92B
| $58.7M | 0.01% |
1,250,162
+338,540
| +37% | +$16.7M |
|
954
Visteon
VC
$2.86B
| $58.7M | 0.01% |
622,287
-64,568
| -9% | -$6.97M |
|
955
Helen of Troy
HELE
$699M
| $58.6M | 0.01% |
260,848
-31,198
| -11% | -$7.14M |
|
956
Lantheus
LNTH
$6.59B
| $58.5M | 0.01% |
2,279,911
-549,403
| -19% | -$14.4M |
|
|
PPD
957
DELISTED
PPD, Inc. Common Stock
PPD
| $58.3M | 0.01% |
1,246,175
-4,993,340
| -80% | -$231M |
|
958
FTI Consulting
FCN
$4.24B
| $58.3M | 0.01% |
432,663
-28,157
| -6% | -$3.91M |
|
959
Fair Isaac
FICO
$24B
| $57.9M | 0.01% |
145,385
-44,673
| -24% | -$21.2M |
|
960
Eastern Bankshares
EBC
$5.37B
| $57.8M | 0.01% |
2,847,692
+65,597
| +2% | +$1.26M |
|
|
MORF
961
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $57.8M | 0.01% |
1,020,219
+646,868
| +173% | +$39.1M |
|
962
General Mills
GIS
$20.8B
| $57.6M | 0.01% |
963,615
+265
| +0% | +$15.7K |
|
|
BOAC.U
963
DELISTED
Bluescape Opportunities Acquisition Corp. Units, each consisting of one Class A ordinary share, and one-half of one redeemable warrant
BOAC.U
| $56.9M | 0.01% |
5,541,165
| – | – |
|
964
GXO Logistics
GXO
$5.56B
| $56.8M | 0.01% |
+723,910
| New | +$56.8M |
|
965
LGI Homes
LGIH
$1.37B
| $56.6M | 0.01% |
399,133
-1,546
| -0.4% | -$244K |
|
966
Tenaya Therapeutics
TNYA
$164M
| $56M | 0.01% |
+2,773,109
| New | +$59.6M |
|
|
ACCD
967
DELISTED
Accolade Inc
ACCD
| $56M | 0.01% |
1,328,123
-69,100
| -5% | -$3.25M |
|
968
Aflac
AFL
$60.7B
| $56M | 0.01% |
1,073,747
-47,722
| -4% | -$2.61M |
|
|
HIBB
969
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $55.4M | 0.01% |
783,503
-14,225
| -2% | -$1.24M |
|
970
Bio-Rad Laboratories Class A
BIO
$9.66B
| $55.4M | 0.01% |
74,206
-7,785
| -9% | -$5.83M |
|
971
Healthcare Realty
HR
$6.58B
| $55.2M | 0.01% |
1,861,613
-44,292
| -2% | -$1.29M |
|
|
DRE
972
DELISTED
Duke Realty Corp.
DRE
| $54.8M | 0.01% |
1,145,651
-14,004
| -1% | -$706K |
|
973
Performance Food Group
PFGC
$16.4B
| $54.4M | 0.01% |
1,169,881
-677,449
| -37% | -$31.2M |
|
974
Lyell Immunopharma
LYEL
$337M
| $54.2M | 0.01% |
182,964
+57,964
| +46% | +$17.4M |
|
|
DRNA
975
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $54.1M | 0.01% |
2,682,596
+699,671
| +35% | +$19.3M |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.